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Malignant melanoma (MM) is one of the most aggressive skin cancer. The therapeutic options remain limited for advanced MM,
and those directed to the neoplastic cells have not brought major survival advantage so far. Immunotherapy is another targeted
option. Ipilimumab, a monoclonal antibody directed to CTLA-4 present on cytotoxic T cells boosts immunity, particularly its
anti-MM activity. Under treatment, the overall survival of patients with MMmetastases is moderately but significantly increased.
The immuno-related adverse eﬀects may be severe and life threatening.
1. Introduction
Malignant melanoma (MM) is one of the most diﬃcult
neoplasms to treat. Unlike most common cancers, the last 20
years have seen no real improvement in systemic therapy for
patients with metastatic MM. Currently the median survival
for patients with metastatic MM is commonly limited to 6–9
months [1, 2]. However, some clinical and histopathological1
evidence exists providing clear demonstration of the ability
of immunotherapy to mediate regression from the early to
the advanced stages of MM [3–5]. The anti-MM lympho-
cytes consist of CD4+ and CD8+ T cells in part presenting
as tumour-infiltrating lymphocytes (TIL). Among them,
various clones of cytotoxic T lymphocytes (CTLs) are key
cells to a specific anti-MM response [6, 7].
The past decade has witnessed much advances in the
understanding of the complexity and redundancy in the
immunological and other biological systems involved inMM
proliferation, invasion, and metastasis [8–11]. A range of
new drugs have been developed to specifically target the
relevant pathways [12]. A number of immunotherapy trials
for metastatic MM including cytokines, vaccines, adoptive
immunotherapy, and their combinations were conducted in
recent years [13]. A new promising MM therapy is emerging
in the field of antibody-based specific targeting [14, 15].
Attempts were made at targeting either MM cells directly or
immune cells involved in the anti-MM activity.
2. CTLA-4
The cytotoxic T-lymphocyte antigen 4 (CTLA-4) corre-
sponding to CD152 is expressed at the surface of some T cells.
CTLA-4 is a member of the immunoglobulin superfamily
[13–15] acting as a downregulator of the immune system
and playing a key role in the inhibition of the anticancer
immunity [16]. With the exception of CD4+CD25+, Foxp3+
T-regulatory cells (Tregs) resting lymphocytes do not express
CTLA-4. Stimulation of CTLA-4 at the CTL surface results in
inhibition of their proliferation.
The CTLA-4 expressed at the CTLs surface binds to
both B7-1 and B7-2 (CD80 and CD86) ligand pairs present
on antigen-presenting cells. Their interaction activates a
cell-signaling cascade leading to the cell cycle arrest of
CTLs [16]. This mechanism results in T-cell anergy and
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interferes with both IL-2 secretion and IL-2 receptor expres-
sion, leading in turn to inhibition of T-cell priming and
immune escape, thereby allowing neoplastic growth [17]. It
produces immune control by inhibition of T-cell responses
contributing to self-antigen tolerance [18]. By contrast,
CD28 binding to B7-1 and B7-2 leads to stimulation of
CTL proliferation and production of IL-2. Because of its
expression on dendritic cells, eﬀector T cells, and regulatory
T cells, CTLA-4 exhibits multiple roles at various stages of
the immune response.
Blocking CTLA-4 is thought to shift the balance of
the immune response, enhancing both the recognition of
tumour antigens and the neoplastic regression [17]. Con-
sequently, this process decreases tolerance to self-antigens,
leading to autoimmunity [5, 18]. CTLA-4 blockade causes
a dynamic shift in the ratio between Tregs and CD8+ TCLs
culminating in eﬀective immune recognition of neoplasms
[19]. This event was documented in posttreatment biopsies
of neoplasms treated with CTLA-4 blockade and correlated
with therapy-mediated tumoral necrosis [20, 21].
3. Tremelimumab
Tremelimumab was a fully human IgG2 anti-CTLA-4 mono-
clonal antibody. Partial response (PR) was initially reported
to reach 6.6% for a period extending 8.9 to 29.8 months
[22, 23]. Despite such early promise, a more recent phase III
trial failed to show a greater survival benefit than traditional
chemotherapy. The drug was subsequently abandoned.
4. Ipilimumab
Ipilimumab (MDX-010: Medarex, Bristol-Myers Squibb) is
a fully humanized IgG1 monoclonal antibody directed to
CTLA-4 [13–15, 19–21, 24–29]. Objective response rates
combining complete response (CR) and PR were in the range
of 5–20% [15, 29]. Disease control rates (CR + PR + stable
disease) were reported averaging 15–30%. In contrast, the
two therapies approved by the FDA, high-dose interleukin-
2, and dacarbazine are each associated with response rate of
only 10 to 20% and a small percentage of CR. They are not
thought to improve overall survival (OS) [30].
Studies involving higher doses of ipilimumab were
associated with higher response rates but with increased
toxicities [19, 24–26]. Ipilimumab is the first therapeutic
agent showing prolonged OS (median OS: 10.1 months) in
patients with metastatic MM. This figure must be compared
to the median survival in such a patient population with
other current therapies generally reaching 6–9 months [1, 2,
28].
Rates of adverse reactions to ipilimumab, particularly
autoimmune events, appear to be dose- and schedule-
dependent. Toxicities associated with ipilimumab diﬀer from
those typically related to regular cytotoxic chemotherapy
[31–33], and they create unique challenges in diagnosis and
clinical management [34]. The majority of adverse events
to ipilimumab are immune mediated, corresponding to the
so-called “immune-related adverse events (irAEs)” [35, 36].
The irAEs aﬀect a range of organs, including the skin,
gastrointestinal tract, and endocrine glands. Antinuclear
antibodies (ANA) are not associated with irAEs, and they
have no diagnostic value in this setting, since many patients
with MM show baseline elevations of ANA titers.
The ipilimumab irAEs are dose-dependent, schedule-
related, and cumulative [34]. Grade 3 and 4 irAE were
reported in 20–30% of patients. Close clinical and laboratory
monitoring is required for early detection and timely initia-
tion of treatment with immunosuppressive therapies. Most
irAEs were manageable and generally reversible under cor-
ticotherapy. Long-term residual irAEs requiring treatment
were reported at 2-year followup in phase III trials, primarily
corresponding to dermatologic eﬀects (rash, vitiligo, and
pruritus), colitis/diarrhea, and endocrine-related adverse
events [25]. In addition, life-threatening irAEs (bowel
perforation due to immune colitis) and treatment-related
mortality were reported in about 2% of ipilimumab-treated
patients. Additional immunosuppression was sometimes
required [37, 38]. Up to 50% of treatment-related deaths
were associated with irAEs [29].
5. Conclusion
Immunotherapy, particularly blockade of the CTLA-4 path-
way, has already proven an eﬀect against advanced MM.
Ipilimumab is the first agent demonstrating promise in the
treatment of metastatic MM. The positive but modest OS
benefit requires more investigations. It seems essential to
tailor treatment options to those patients most likely to
benefit, especially because the treatment is associated with
frequent and sometimes life-threatening irAE. Overall, the
inherent risks of immunotherapy require judicious use in
appropriately selected patients by well-informed clinicians
and patients.
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